Clinical Trial Search

Primary: Number of Participants Who Had Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs) — 38; 95; 1; 4 Participants

Primary: Percent Change in Mean Pulmonary Artery Pressure in the Whole Cohort. — -25 percent change

Primary: Number of Eyes With a Loss of >2 Lines for Best Spectacle Corrected Visual Acuity (BSCVA) — 2 eyes

Primary: Number of Participants With Recurrence and Recurrence Rate at 1 Year Following Narrow Band Imaging and TURB (Arm A) Versus White Light Trans Urethral Resection of…

Primary: Number of Participants Requesting Pain Medication in Different Patterns Over Time — 94; 20; 22; 19 Participants

Primary: Change From Baseline to 8 Weeks in Montgomery-Asberg Depression Rating Scale (MADRS) — -8.13; -5.76 units on a scale

Primary: Dietary Intake as Measured by Percent Energy From Fat — 33.75; 34.9; 33.72; 35.05 percent energy from fat — p=0.1073

Primary: Change From Randomization to Week 8 in the Montgomery-Asberg Depression Rating Scale (MADRS) Total Score — -9.36; -9.59; -9.36 units on a scale — p=0.997

Primary: Disease Recurrence Rate — 27.86; 40 percentage of patients with recurrence — p=0.01

Primary: Opioid Blockade Following Administration of Hydromorphone Challenge As Measured Using the Subjective Opioid Effects Rating for the Question "Do You Like the Drug?"…

Primary: Incidence of Adverse Events and Dose Limiting Adverse Events — 0; 69; 47; 44 percentage of participants

Primary: Change From Baseline to 24 Week Endpoint in Hemoglobin A1c (HbA1c) — -0.15; -0.45; -0.78; -0.92 percentage of Hemoglobin A1c (HbA1c) — p=0.094

Primary: Response to Urinary Incontinence as a Composite Measure of Efficacy of add-on Mirabegron — 12; 23 Participants

Primary: Number of Subjects With a Vaccine Response for Anti-glycoprotein E (Anti-gE) in GSK1437173A Group — 361 Participants

Primary: Mean Change in Glycosylated Hemoglobin A1c (HbA1c) — 0.11; -0.83; -0.65; -0.66 percentage of HbA1c — p=0.0296